F. Lerebours

1.7k total citations
49 papers, 713 citations indexed

About

F. Lerebours is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, F. Lerebours has authored 49 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 27 papers in Cancer Research and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in F. Lerebours's work include Breast Cancer Treatment Studies (24 papers), Advanced Breast Cancer Therapies (14 papers) and HER2/EGFR in Cancer Research (14 papers). F. Lerebours is often cited by papers focused on Breast Cancer Treatment Studies (24 papers), Advanced Breast Cancer Therapies (14 papers) and HER2/EGFR in Cancer Research (14 papers). F. Lerebours collaborates with scholars based in France, United States and Belgium. F. Lerebours's co-authors include Rosette Lidereau, Roman Rouzier, Marc Espié, Hugues de Thé, Yves Beuzard, Anne de Roquancourt, François Plassa, Anne Janin, P Bertheau and E Turpin and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

F. Lerebours

48 papers receiving 696 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Lerebours France 13 437 264 212 104 90 49 713
Yanina Jansen Belgium 15 595 1.4× 221 0.8× 345 1.6× 88 0.8× 156 1.7× 48 887
Shelly Seward United States 15 390 0.9× 157 0.6× 298 1.4× 68 0.7× 116 1.3× 34 898
Anne Uyei United States 9 559 1.3× 111 0.4× 303 1.4× 37 0.4× 88 1.0× 15 771
Hideaki Mitsui Japan 18 320 0.7× 206 0.8× 393 1.9× 79 0.8× 290 3.2× 47 863
Véronique Haddad France 11 328 0.8× 89 0.3× 277 1.3× 41 0.4× 105 1.2× 23 550
Claudia Vollbrecht Germany 20 378 0.9× 252 1.0× 315 1.5× 115 1.1× 295 3.3× 45 820
Suthee Rapisuwon United States 11 683 1.6× 104 0.4× 329 1.6× 81 0.8× 158 1.8× 30 997
Anette Weber Germany 14 490 1.1× 104 0.4× 370 1.7× 26 0.3× 87 1.0× 18 882
Jan P. Baak Norway 14 239 0.5× 206 0.8× 279 1.3× 145 1.4× 51 0.6× 24 847
Alexandre Harlé France 17 377 0.9× 377 1.4× 349 1.6× 81 0.8× 165 1.8× 70 805

Countries citing papers authored by F. Lerebours

Since Specialization
Citations

This map shows the geographic impact of F. Lerebours's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Lerebours with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Lerebours more than expected).

Fields of papers citing papers by F. Lerebours

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Lerebours. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Lerebours. The network helps show where F. Lerebours may publish in the future.

Co-authorship network of co-authors of F. Lerebours

This figure shows the co-authorship network connecting the top 25 collaborators of F. Lerebours. A scholar is included among the top collaborators of F. Lerebours based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Lerebours. F. Lerebours is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Héquet, Delphine, et al.. (2021). Prosigna test in breast cancer: real-life experience. Breast Cancer Research and Treatment. 188(1). 141–147. 9 indexed citations
3.
Pierga, J-Y, Gaëlle Pierron, Steven Ballet, et al.. (2021). 113P Efficacy of oral etoposide associated with trastuzumab in HER2-positive metastatic breast cancer: Results from the Institut Curie’s database. Annals of Oncology. 32. S71–S71. 1 indexed citations
4.
Delaloge, Suzette, Sylvain Dureau, Véronique D’Hondt, et al.. (2021). 63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study. Annals of Oncology. 32. S48–S48. 1 indexed citations
5.
Lerebours, F., Sophie Vacher, J M Guinebretière, et al.. (2020). Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?. Journal of Advanced Research. 28. 77–85. 9 indexed citations
6.
Carton, Matthieu, F. Lerebours, Étienne Brain, et al.. (2020). Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer. The Breast. 54. 303–310. 9 indexed citations
7.
Pierga, J-Y, Étienne Brain, Roman Rouzier, et al.. (2019). Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database. Breast Cancer Research and Treatment. 178(3). 505–512. 7 indexed citations
8.
Vaz-Luís, Inês, Antonio Di Meglio, Mayssam El-Mouhebb, et al.. (2018). Breast cancer (BC) related fatigue: A longitudinal investigation of its prevalence, domains and correlates. Annals of Oncology. 29. viii605–viii605. 3 indexed citations
9.
Rossi, Luigi, Enora Laas, Patrick Mallon, et al.. (2015). Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. British Journal of Cancer. 113(7). 996–1002. 28 indexed citations
10.
Gonçalvès, Anthony, Jean‐Yves Pierga, Jean-­Marc Ferrero, et al.. (2015). UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Annals of Oncology. 26(8). 1692–1697. 14 indexed citations
11.
Boutros, C., Chafika Mazouni, F. Lerebours, et al.. (2015). A preoperative nomogram to predict the risk of synchronous distant metastases at diagnosis of primary breast cancer. British Journal of Cancer. 112(6). 992–997. 8 indexed citations
12.
Laas, Enora, Patrick Mallon, Myriam Deloménie, et al.. (2015). Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. British Journal of Cancer. 112(5). 912–917. 11 indexed citations
13.
Langer, A., et al.. (2014). A single-institution study of 117 pregnancy-associated breast cancers (PABC): Presentation, imaging, clinicopathological data and outcome. Diagnostic and Interventional Imaging. 95(4). 435–441. 51 indexed citations
14.
15.
Lerebours, F.. (2005). Traitements néoadjuvants du cancer du sein : marqueurs géno- et phénotypiques de la réponse thérapeutique et du pronostic. Pathologie Biologie. 54(4). 209–214. 2 indexed citations
16.
Bertheau, P, François Plassa, Marc Espié, et al.. (2002). Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. The Lancet. 360(9336). 852–854. 126 indexed citations
17.
Lerebours, F. & Rosette Lidereau. (2002). Molecular alterations in sporadic breast cancer. Critical Reviews in Oncology/Hematology. 44(2). 121–141. 31 indexed citations
18.
Girault, Igor, F. Lerebours, Sengül Tozlu, et al.. (2002). Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas. The Journal of Steroid Biochemistry and Molecular Biology. 82(4-5). 323–332. 27 indexed citations
19.
Cottu, P., J.M. Extra, Marc Espié, et al.. (2001). High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study. British Journal of Cancer. 85(9). 1240–1246. 6 indexed citations
20.
Marty, M., Marc Espié, Paul Cottu, C. Cuvier, & F. Lerebours. (1999). Optimizing Chemotherapy for Patients with Advanced Breast Cancer. Oncology. 57(Suppl. 1). 21–26. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yanina Jansen Breakdown of academic impact, for papers by Shelly Seward Breakdown of academic impact, for papers by Anne Uyei Breakdown of academic impact, for papers by Hideaki Mitsui Breakdown of academic impact, for papers by Véronique Haddad Breakdown of academic impact, for papers by Claudia Vollbrecht Breakdown of academic impact, for papers by Suthee Rapisuwon Breakdown of academic impact, for papers by Anette Weber Breakdown of academic impact, for papers by Jan P. Baak Breakdown of academic impact, for papers by Alexandre Harlé
Rankless by CCL
2026